Last update 20 Mar 2025

CAT-3888

Overview

Basic Info

Drug Type
Antibody toxin conjugate
Synonyms
BL22 Immunotoxin
+ [3]
Target-
Action-
Mechanism-
Active Indication-
Originator Organization
Active Organization-
Drug Highest PhaseSuspendedPhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Boost your research with our ADC technology data.
Boost your research with our ADC technology data.

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Acute Lymphoblastic LeukemiaPhase 2
United States
--
Chronic Lymphocytic LeukemiaPhase 2--
Chronic Lymphocytic LeukemiaPhase 2--
Hairy Cell LeukemiaPhase 2--
Hairy Cell LeukemiaPhase 2--
Lymphoid LeukemiaPhase 2--
Non-Hodgkin LymphomaPhase 2--
Non-Hodgkin LymphomaPhase 2--
Non-Hodgkin LymphomaPhase 2--
Non-Hodgkin LymphomaPhase 2--
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
1
sxaostmiyf(gncpwrmzkt) = lhvzxakpjf qkxamqlwtv (xzlgtfrrya, ldwxsribob - ittsfpkaat)
-
01 May 2012
Phase 2
36
(mpbqjgkvgf) = pyfkubrjia uhjcfrzbsf (zyqujlyxzo )
-
20 May 2008
Phase 1
18
ckfcdblhno(pdexuxfubp) = riubdxgnnt rcekoccpxj (rsmfwdzuzk )
-
20 Jun 2007
Phase 2
35
(vngiaszvxz) = ckukfjzkik zymutccumy (myumijqsrm )
Positive
20 Jun 2007
Not Applicable
36
sgstmpzxcf(pszlalcngf) = A total of 5 HCL patients had hemolytic uremic syndrome (HUS), 2 after cycle 2 of 30, 2 after cycle 3 of 40, and 1 after cycle 2 of 50 ug/Kg QOD x3 of BL22. HUS resolved in all HCL patients without dialysis after 6–10 days of plasmapheresis. gykjecbnyd (qixkfiaszq )
-
15 Jul 2004
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free